Adherex Technologies (NASDAQ:FENC) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Adherex Technologies (NASDAQ:FENC) released its quarterly earnings results on Thursday. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.03, Zacks reports. The business had revenue of $15.11 million for the quarter, compared to analyst estimates of $13.90 million. Adherex Technologies had a negative net margin of 22.62% and a negative return on equity of 183.18%.

Here are the key takeaways from Adherex Technologies’ conference call:

• Fennec reported Q1 2026 net product sales of $15.1 million, up about 73% year over year, marking the sixth consecutive quarter of sales growth under the current commercial leadership.
• The company said its commercial push is gaining traction after launching Project Ignite, expanding the field force to 14 new territories and 4 frontline managers and increasing target prescribers from about 1,300 to more than 5,000.
• Operational metrics improved meaningfully, including a 48% quarter-over-quarter increase in completed infusions through Fennec HEARS, conversion rates reaching the company’s 80% benchmark, and adherence running around 80%.
• Management highlighted growing clinical interest in PEDMARK beyond pediatrics, including three investigator-initiated studies and four ASCO abstracts, with potential expansion into AYA and adult patient populations and new tumor types.
• Fennec ended the quarter with $40.1 million in cash and said it generated positive cash flow in Q1, but it also expects Q2 ending cash to be lower and noted it does not anticipate receiving the German milestone payment from partner Norgine.

Adherex Technologies Stock Performance

Shares of NASDAQ FENC opened at $9.24 on Friday. Adherex Technologies has a 1 year low of $5.65 and a 1 year high of $9.92. The firm’s 50 day moving average price is $6.89 and its 200 day moving average price is $7.56. The firm has a market cap of $319.15 million, a P/E ratio of -27.18 and a beta of 0.91.

Analysts Set New Price Targets

Several research firms have recently commented on FENC. B. Riley Financial began coverage on shares of Adherex Technologies in a research report on Thursday, February 12th. They issued a “buy” rating and a $16.00 price target on the stock. Zacks Research lowered shares of Adherex Technologies from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Tuesday, April 21st. Wedbush restated an “outperform” rating and set a $13.00 target price on shares of Adherex Technologies in a research report on Thursday, April 16th. Finally, Wall Street Zen lowered shares of Adherex Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Adherex Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $14.80.

Insider Transactions at Adherex Technologies

In related news, Director Rosty Raykov sold 10,781 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $6.47, for a total transaction of $69,753.07. Following the sale, the director owned 121,451 shares in the company, valued at approximately $785,787.97. This trade represents a 8.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.73% of the company’s stock.

Institutional Trading of Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC purchased a new stake in Adherex Technologies Inc. (NASDAQ:FENC) during the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.